Pheast Therapeutics is a pre-clinical immuno-oncology company developing checkpoint therapies that activate the innate immune system to combat cancer. Its primary program targets the surface protein CD24, a 'don't eat me' signal used by cancers such as ovarian and breast to avoid clearance by intra-tumoral macrophages. The company leverages a proprietary discovery platform to develop additional tumor-specific immunotherapies. Pheast is led by scientific experts including Dr. Amira Barkal, Dr. Irving Weissman, Dr. Ravi Majeti, and Dr. Roy Maute. The company intends to use the new funds to expand management, scientific, and administrative teams and to advance R&D for its pipeline toward the clinic. Pheast is based in Palo Alto, California.

Total raised

$76M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2022